supported by National Natural Science Foundation of China(Grant Nos.81871990 and 31671448);Yunnan Applicative and Basic Research Program(Grant Nos.2019FY003030 and 202101AV070002);a grant(2019KF006)from Conservation and Utilization of Bio-Resources in Yunnan(YNCUB).
Objective:The BRAF inhibitor,vemurafenib,has been widely used in the treatment of patients with melanoma-bearing BRAFV600E mutations.While the initial response to vemurafenib is usually excellent,the majority of patie...
This work was supported by the National Natural Science Foundation of China(81730096,81873026,81973499);the CAMS Innovation Fund for Medical Sciences(CIFMS)(2016-I2M-1-004);the Drug Innovation Major Project(2018ZX09711001-003-005,2018ZX09711001-002-007);the Beijing Key Laboratory of New Drug Mechanisms and Pharmacological Evaluation Study(BZ0150);the opening Program of Shanxi Key Laboratory of Chinese Medicine Encephalopathy(CME-OP-2017001);the High-End Foreign Experts introduction program(G20200001485).
Newborns suffering from hypoxia-ischemia (HI) brain injury still lack effective treatment. Proline-rich tyrosine kinase 2 (Pyk2) is a non-receptor tyrosine kinase, which is highly correlated with transient ischemic br...